YieldMax NVDA Option Income Strategy ETF vs Relay Therapeutics Inc. Common Stock — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.57 (market cap $1.45B), while Relay Therapeutics Inc. Common Stock trades at $18.27 (market cap $3.82B). The key difference: Relay Therapeutics Inc. Common Stock is far larger — about 2.6× YieldMax NVDA Option Income Strategy ETF's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 43 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| NVDY | RLAY | |
|---|---|---|
Market Cap | $1.45B | $3.82B |
Volume | 1,943,739 | 4,332,079 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $20.75 |
52-Week Low | $11.58 | $6.03 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | — | $2.93B |
Signals from Pluang's Aura AI — not financial advice
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.64, down 2.84% on the day amid a bearish technical signal. The fund generates income through options on NVIDIA stock but faces headwinds from declining volatility, which caps upside participation and has led to recent analyst downgrades. Weekly dividend distributions continue, but concerns over net asset value erosion persist.
The outlook for NVDY is cautious, as its high distribution yield comes with structural limitations on capital appreciation. Investment opportunity lies in income generation for risk-tolerant investors, but risks include NAV erosion and dependency on NVIDIA's volatility. Analyst sentiment has shifted to hold, reflecting diminished attractiveness amid lower option premiums.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →